Patients who are hepatitis B core antibody positive and or have positive hepatitis B surface antigen will require hepatology consultation; the risk/benefit profile of transplant and hepatitis B will be discussed with the patient and eligibility determined by the PI or the LAI
Patient may have a hepatitis C infection; however, each patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the PI or the LAI
RECIPIENT: Chronic active hepatitis B; patient may be hepatitis B core antibody positive; for patients with a concomitant positive hepatitis B surface antigen, patients will require a hepatology consultation; the risk-benefit profile of transplant and hepatitis B will be discussed with the patient, and eligibility determined by the PI or lead associate investigator
Chronic active hepatitis B; patient may be hepatitis B core antibody positive; for patients with a concomitant positive hepatitis B surface antigen, patients will require a hepatology consultation; the risk-benefit profile of transplant and hepatitis B will be discussed with the patient, and eligibility determined by the PI and the protocol chairperson
Chronic active hepatitis B; patient may be hepatitis B core antibody positive; for patients with concomitant positive hepatitis B surface antigen, patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis B will be discussed with the patient and eligibility determined by the principal investigator and LAI
Hepatitis C infection; patient may have hepatitis C infection; however, each patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the principal investigator and LAI
Chronic active hepatitis B; patients may be hepatitis B core antibody positive; for patients with concomitant positive hepatitis B surface antigen, patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis B will be discussed with the patient and eligibility determined by the principal investigator
Hepatitis C infection; patient may have a hepatitis C infection; however, each patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the principal investigator and lead associate investigator
Chronic active hepatitis B; patient may be hepatitis B core antibody positive; for patients with concomitant positive hepatitis B surface antigen, patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis B will be discussed with the patient and eligibility determined by the principal investigator and protocol chairperson
Hepatitis C infection; patient may have hepatitis C infection; however, each patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the principal investigator and protocol chairperson
DONOR: Donors must be HIV negative, hepatitis B surface antigen negative, and hepatitis C antibody negative; donors with a history of hepatitis B or hepatitis C infection may be eligible; however, eligibility determination of such patients will require a hepatology consultation; the risk/benefit of the transplant and the possibility of transmitting hepatitis will be discussed with the patient and eligibility will then be determined by the principal investigator
